Thursday, September 10, 2026
← Back to archivePolicy
Policy•STAT News•Sep 10, 2026
Opinion: John Fetterman’s post-stroke, politically problematic behaviors offer lessons about brain health on Capitol Hill
background ▾
- •Apathy and behavioral changes in stroke survivors are clinically recognized neurological syndromes affecting ~33% of survivors, not character failings—distinguishing this from depression and requiring medical rather than moral interpretation
- •Frontal lobe damage from stroke (affecting language centers) often also damages circuitry governing judgment, moral reasoning, and behavioral inhibition, with documented effects on personality since the Phineas Gage case of 1848
Policy•STAT News•Sep 10, 2026
Trump officials say AI will help save rural health care. Some leaders in the field don’t believe it
background ▾
- •Trump administration claims AI can help offset $1 trillion in Medicaid cuts to rural healthcare, but rural providers report AI tools improve workflows without reducing costs
- •Rural health systems face a critical barrier: AI implementation is expensive and requires substantial infrastructure investment that underfunded systems cannot sustain, potentially widening disparities
- •Early AI adoption (ambient scribes, predictive analytics) shows operational benefits but no proven large-scale cost savings, creating a gap between policy promises and clinical/financial reality
Penobscot Community Health CareMaineHealth
→ Read original articlePolicy•STAT News•Sep 9, 2026
Coroner releases details of infants who died amid growing Pennsylvania measles outbreak
background ▾
- •Coroner-confirmed measles deaths in infants under vaccination age, with CDC withholding official classification despite medical evidence, signaling potential politicization of public health data reporting
- •Health Secretary Kennedy's repeated questioning of measles death causality contradicts coroner findings and CDC expertise, raising concerns about institutional independence and vaccine confidence erosion
- •Measles vaccination coverage has fallen below the 95% threshold needed for community immunity, with outbreak now spanning 37 Pennsylvania counties—watch for whether CDC maintains data independence and how vaccination rates respond to vaccine confidence erosion
measles vaccine
→ Read original articlePolicy•Fierce Biotech•Sep 9, 2026
FDA solidifies CDER, CBER leadership posts as commissioner confirmation awaits
background ▾
- •Permanent appointment of Davis and Mikhail ends leadership instability at CDER and CBER and represents a return to industry-aligned regulatory leadership after controversial departures of senior staff.
- •New deputy commissioner position for AI and technology signals FDA's commitment to modernizing its regulatory framework for emerging technologies and emerging tech-enabled drug development.
- •Watch for Overton's Senate confirmation process and whether her tenure as FDA commissioner will align with the apparent stabilization strategy embodied by Davis and Mikhail's permanent appointments.
AmarinMerck & Co.Usona Institute
→ Read original articlePolicy•Endpoints News•Sep 9, 2026
ARPA-H picks UpDoc, Tempus and Atman to build AI tools for heart disease
background ▾
- •ARPA-H is funding three AI companies to develop FDA-authorized agentic AI tools for heart disease, indicating accelerating government investment in clinical AI infrastructure
- •This initiative may establish precedent for regulatory pathways and standards for agentic AI in clinical practice, with implications for how FDA evaluates autonomous clinical decision systems
- •Watch for: regulatory guidance updates, trial design announcements for these tools, and whether ARPA-H funding influences FDA approval timelines for AI medical devices
UpDocTempus AIAtman Health
→ Read original articleMarket Access
Market Access•Fierce Biotech•Sep 9, 2026
Luma locks down 15-year, $410M fund for life science investments
background ▾
- •Luma Group closed a $410M inaugural VC fund with 15-year commitment structure, signaling investor confidence in patient capital models for early biotech development
- •Portfolio company Vaccine Company's $1.55B acquisition by Eli Lilly provides early proof-of-concept for fund's investment thesis and de-risks future returns
Luma GroupCharacter BiosciencesCoultreon Biopharma
→ Read original articleMarket Access•STAT News•Sep 9, 2026
Telemedicine company offers GLP-1s for addiction
background ▾
- •Quel is the first telemedicine platform specifically built to offer GLP-1s off-label for addiction treatment, expanding a model validated at elite treatment centers to a broader patient population
- •Clinical evidence is rapidly accumulating with dozens of ongoing trials, but regulatory approval remains absent, creating both opportunity and compliance risk
- •The business model depends on off-label prescribing and telemedicine infrastructure in a high-need market with minimal FDA guidance
QuelCaron Treatment Centerssemaglutide
→ Read original articleMarket Access•Endpoints News•Sep 10, 2026
Pharma investment in UK picks up after last year’s lull, trade group says
background ▾
- •UK government policy shift toward higher medicine pricing and closer pharma engagement is driving renewed industry investment after a period of decline
Market Access•Fierce Biotech•Sep 9, 2026
nPhase launches AI clinical data management platform to soup up sponsor trial design
background ▾
- •nPhase.ai's SCE component claims to transform submission timelines from months to weeks by automating CDISC-compliant data harmonization and regulatory document generation
- •The platform addresses growing clinical trial complexity (avg. phase 3 protocol: 6M data points) and fragmented data sources by creating AI-ready, harmonized datasets in near real-time
nPhaseCDISC
→ Read original articleMarket Access•Fierce Biotech•Sep 9, 2026
Labcorp snaps up MLM Medical Labs to boost laboratory footprint
background ▾
- •Labcorp now operates wholly owned central laboratory networks across four continents (North America, Europe, Asia, Africa), uniquely positioning it for global clinical trial support
- •The acquisition adds Africa's first fully CAP-accredited central laboratory to Labcorp's portfolio, expanding regional expertise for emerging and established pharma sponsors
LabcorpMLM Medical Labs
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 9, 2026
Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy
background ▾
- •Menin inhibition is being repositioned from oncology (where Komzifti and Revuforj recently won FDA approvals for AML) into diabetes by targeting β-cell dysfunction rather than managing symptoms
- •Strong syndicate backing from Eli Lilly—a major diabetes player—alongside BVF Partners and T1D Fund validates the scientific rationale and commercial potential
- •Watch for preclinical data presentation at EASD in late September and the timing of IND filing; commercial validation will ultimately depend on FIH trial safety/efficacy and whether menin inhibition proves superior to existing diabetes therapies
Kura OncologyCaspian TherapeuticsEli LillyKO-7246KomziftiRevuforj
→ Read original articleClinical Trials•Fierce Biotech•Sep 9, 2026
Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock
background ▾
- •Dabogratinib demonstrated superior safety vs. pan-FGFR inhibitors (4.5% treatment-related grade 3+ AEs, no dose reductions/discontinuations at 60 mg), but 63% CR in single-marker patients fell short of the 70% analyst benchmark and J&J Balversa's 72% at three months.
- •Tyra is expanding to a 70-mg cohort based on data suggesting higher drug exposure may improve ablative efficacy in multiple-marker patients, introducing dose-finding uncertainty for the registrational program.
- •The company's bet on single-marker three-month CR as a proxy for longer-term adjuvant efficacy remains unvalidated and represents a key clinical and regulatory risk for the pivotal trial launching in 2025.
Tyra BiosciencesJohnson & JohnsondabogratinibBalversa
→ Read original articleClinical Trials•Fierce Biotech•Sep 9, 2026
GV-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturing
background ▾
- •ETX101 demonstrated 78% seizure reduction in phase 1/2, positioning it as a potentially transformative one-time AAV9 gene therapy for Dravet syndrome's underlying genetic cause
- •Significant funding and manufacturing investment de-risk ETX101's path to pivotal trial and potential registration, despite competitive pressure from Biogen/Stoke's antisense program
- •Monitor ETX101 pivotal trial readout timing and ETX301 IND submission in 2027; track Biogen/Stoke's zorevunersen phase 3 results (Q3 2026) as the primary near-term competitive catalyst
Encoded TherapeuticsGV (Google Ventures)ARCH Venture PartnersETX101ETX301zorevunersen
→ Read original articleClinical Trials•Endpoints News•Sep 9, 2026
Key research behind orexin and narcolepsy wins Lasker Award
background ▾
- •Lasker Award recognition confirms the critical importance of orexin biology in narcolepsy pathogenesis, providing scientific credibility to the orexin-targeted drug development class
- •The research spanned multiple experimental models (mice, dogs, viral studies), demonstrating the translational pathway from basic science to clinical understanding of this neurological disorder
Clinical Trials•Endpoints News•Sep 9, 2026
Compass posts positive psilocybin data; Solstice makes $225M debut
background ▾
- •Compass Pathways' one-year psilocybin data demonstrates durability of clinical effect, a critical finding for justifying the intensive psychedelic-assisted therapy model to regulators and payers
- •Solstice's $225M Series B valuation signals strong venture appetite for psychedelic-assisted therapies despite earlier-stage development profile compared to traditional small molecules
- •Watch for Compass's regulatory filings (likely IND/NDA-track decisions) and real-world evidence on therapy accessibility and reimbursement model viability
Compass PathwaysSolstice NeuroscienceLumaPsilocybin
→ Read original article